Jeremy Freeman, PhD
About Jeremy Freeman, PhD
Jeremy Freeman, PhD, serves as the Senior Director of Pharmacokinetics at Nektar Therapeutics, where he has worked since 2022. He has extensive experience in drug development, having held various roles at companies such as ZymoGenetics, Omeros Corporation, and AbbVie, and is well-versed in regulatory compliance and biomarker analysis.
Current Role at Nektar Therapeutics
Jeremy Freeman serves as the Senior Director of Pharmacokinetics at Nektar Therapeutics, a position he has held since 2022. His role involves overseeing pharmacokinetic studies and ensuring compliance with regulatory standards in drug development. Nektar Therapeutics is located in Shoreline, Washington, where Freeman applies his extensive knowledge of pharmacokinetics to support the development of innovative therapeutics.
Previous Experience in Drug Development
Freeman has a diverse background in drug development, having worked at several organizations. He was a Senior Scientist in Pharmacodynamic Analysis at ZymoGenetics from 2005 to 2011 and later served as a Principal Scientist in Biomarker Development at the same company for one year. He also held the position of Associate Director of Bioanalytical DMPK at Omeros Corporation from 2017 to 2022. His experience includes contributing to health authority submissions and participating in Pre-IND and Type C meetings with the FDA.
Educational Background
Jeremy Freeman earned his Bachelor of Arts in Biology from Cornell University, where he studied from 1990 to 1994. He later pursued a Ph.D. in Molecular Biology at Princeton University, completing his studies from 1994 to 1999. His academic background provides a strong foundation for his expertise in pharmacokinetics and drug development.
Expertise in Regulatory Compliance
Freeman is well-versed in regulatory compliance, familiar with FDA, ICH, and EMA guidance documents. He utilizes GLP-compliant validation techniques for immuno- and cell-based assays. His experience includes preparing submissions using electronic Common Technical Document (eCTD) formats, which are essential for regulatory processes in drug development.
Technical Skills and Methodologies
Freeman possesses a range of technical skills relevant to pharmacokinetics and drug development. He is experienced in cellular immunophenotyping by flow cytometry and PGt analyses. He has implemented biomarker analyses, including the quantification of serum markers and assessment of gene expression using qPCR. Additionally, he is skilled in managing and analyzing nonclinical and clinical data using software such as Microsoft Excel, JMP, WinNonlin, and Berkeley Madonna.